Breast Cancer and Genomic Medicine

Genomic and Personalized Medicine, Two-Vol Set

Volumn , Issue , 2009, Pages 869-878

  Huang, Erich S ^a   Huang, Andrew T ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Koo Foundation Sun Yat Sen Cancer Center   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449514947     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-369420-1.00072-X     Document Type: Chapter

References (28)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403(6769):503-511.
2. Bezwoda W.R., Esser J.D., Dansey R., Kessel I., Lange M. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991, 68(4):867-872.
3. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., Joshi M.B., Harpole D., Lancaster J.M., Berchuck A., Olson J.A., Marks J.R., Dressman H.K., West M., Nevins J.R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439(7074):353-357.
4. Chang H.Y., Sneddon J.B., Alizadeh A.A., Sood R., West R.B., Montgomery K., Chi J.T., van de Rijn M., Botstein D., Brown P.O. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2(2):E7.
5. Chang H.Y., Nuyten D.S., Sneddon J.B., Hastie T., Tibshirani R., Sørlie T., Dai H., He Y.D., van't Veer L.J., Bartelink H., van de Rijn M., Brown P.O., van de Vijver M.J. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102(10):3738-3743.
6. Cheng S.H., Tsou M.H., Liu M.C., Jian J.J., Cheng J.C., Leu S.Y., Hsieh C.Y., Huang A.T. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000, 63(3):213-223.
7. Chien K.R. Herceptin and the heart - a molecular modifier of cardiac failure. N Engl J Med 2006, 354(8):789-790.
8. Chu K.C., Tarone R.E., Kessler L.G., Ries L.A., Hankey B.F., Miller B.A., Edwards B.K. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996, 88(21):1571-1579.
9. Clemons M., Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001, 344(4):276-285.
10. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001, 358(9291):1389-1399. Collaborative Group on Hormonal Factors in Breast Cancer.
11. Ein-Dor L., Kela I., Getz G., Givol D., Domany E. Outcome signature genes in breast cancer: is there a unique set?. Bioinformatics 21(2), 2005, 171-178.
12. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S., Nobel A.B., van't Veer L.J., Perou C.M. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355(6):560-569.
13. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286(5439):531-537.
14. Hartmann L.C., Schaid D.J., Woods J.E., Crotty T.P., Myers J.L., Arnold P.G., Petty P.M., Sellers T.A., Johnson J.L., McDonnell S.K., Frost M.H., Jenkins R.B. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340(2):77-84.
15. Huang E., Cheng S.H., Dressman H., Pittman J., Tsou M.H., Horng C.F., Bild A., Iversen E.S., Liao M., Chen C.M., West M., Nevins J.R., Huang A.T. Gene expression predictors of breast cancer outcomes. Lancet 361(9369), 2003, 1590-1596.
16. Huang E., Ishida S., Pittman J., Dressman H., Bild A., Kloos M., D'Amico M., Pestell R.G., West M., Nevins J.R. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet 2003, 34(2):226-230.
17. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M.J. Cancer statistics. CA Cancer J Clin 2006, 56(2):106-130.
18. Manni A., Arafah B., Pearson O.H. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer 1980, 46(12 Suppl):2838-2841.
19. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826.
20. Peto J., Mack T.M. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000, 26(4):411-414.
21. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., Cragun J., Cottrill H., Kelley M.J., Petersen R., Harpole D., Marks J., Berchuck A., Ginsburg G.S., Febbo P., Lancaster J., Nevins J.R. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12(11):1294-1300.
22. Pritchard K.I., Shepherd L.E., O'Malley F.P., Andrulis I.L., Tu D., Bramwell V.H., Levine M.N. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006, 354(20):2103-2111. National Cancer Institute of Canada Clinical Trials Group.
23. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van't Veer L., Garber J.E., Evans G.R., Narod S.A., Isaacs C., Matloff E., Daly M.B., Olopade O.I., Weber B.L. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004, 22(6):1055-1062.
24. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
25. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lønning P., Børresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874.
26. Thor A.D., Berry D.A., Budman D.R., Muss H.B., Kute T., Henderson I.C., Barcos M., Cirrincione C., Edgerton S., Allred C., Norton L., Liu E.T. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998, 90(18):1346-1360.
27. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347(25):1999-2009.
28. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108(2):171-182.